Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090839 | 0.84 | KDM4E (0.51) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL890574 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| Bromide SCHEMBL3957044 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL10970382 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL2715301 | 0.82 | MAPT (0.46) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL3955368 | 0.82 | MAPT (0.52) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL3155115 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| Bromide SCHEMBL5132009 | 0.81 | MAPT (0.51) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL3959035 | 0.80 | MAPT (0.60) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL5131549 | 0.79 | KDM4E (0.62) | KDM4EALDH1A1GLAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0156121-A2 | Substituted pyrimidinyl organophosphorus compounds, compositions thereof, methods of controlling pests and intermediates in the preparation of the compounds | UNIROYAL, INC. (US) | 1985-10-02 | — | — | EP | claimed |
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2445898-A2 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES AS PI3K INHIBITORS | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2010151735-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151735-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | KDM4E 1436/4885ALDH1A1 3735/4885GLA 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.